FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Sunshine Biopharma, Inc. Stock AnalysisComprehensive stock analysis for Sunshine Biopharma, Inc. (SBFMW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSBFMW
SBFMW
Sunshine Biopharma, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SBFMW
Home🔹Stocks🔹Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc.

SBFMW•NASDAQ

Sunshine Biopharma, Inc.

SBFMW•NASDAQ
Market cap
$175.20K
Sentiment

Your view on SBFMW

Mkt Cap
$175.20K
Sentiment
Your view
SBFMW
Sunshine Biopharma, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SBFMW
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Sunshine Biopharma, Inc.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Steve N. Slilaty
Headquarters
333 Las Olas Way, Fort Lauderdale, FL, US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Steve N. Slilaty
Headquarters
333 Las Olas Way, Fort Lauderdale, FL, US
Description

Sunshine Biopharma, Inc. operates as a pharmaceutical and nutritional supplement company primarily dedicated to the research and development of innovative anticancer drugs. The company's pipeline includes Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin. This compound is currently in development to address a broad spectrum of cancers, such as leukemia, lymphoma, and tumors affecting the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver. Significantly, Adva-27a has also shown effectiveness against multidrug-resistant cancer cells, including those associated with pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma. Another key therapeutic in development is SBFM-PL4, an anti-coronavirus treatment compound. In addition to its pharmaceutical endeavors, Sunshine Biopharma offers a range of nutritional supplements, including the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, and continues to develop and market other scientifically-formulated nutritional products. The company has forged a licensing agreement with the University of Georgia to further the development of its lead anti-coronavirus compound, SBFM-PL4. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Sunshine Biopharma, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Sunshine Biopharma, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Sunshine Biopharma, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Sunshine Biopharma, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Sunshine Biopharma, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Sunshine Biopharma, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Sunshine Biopharma, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Sunshine Biopharma, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Sunshine Biopharma, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Sunshine Biopharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Sunshine Biopharma, Inc.. Press releases and market coverage, newest first.

News

Latest Market News